Svelte Medical Systems
Delivers novel products in the coronary stent market to curb key clinical issues by improving stent deliverability.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD31—46m (Dealroom.co estimates Mar 2014.)
New Providence Iowa (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.3m | Early VC | ||
$6.0m | Debt | ||
$9.7m | Debt | ||
$18.8m | Late VC | ||
$5.0m | Debt | ||
$1.8m | Debt | ||
$5.0m | Early VC | ||
$44.4m | Growth Equity VC | ||
$4.0m | Debt | ||
$22.0m | Late VC | ||
Total Funding | AUD149m |
Related Content
Recent News about Svelte Medical Systems
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.